Systemic Janus Kinase Inhibitor Treatment for Vitiligo: An Evidence-Based Review

Description

Vitiligo is an immune-mediated condition characterized by melanocyte loss. While topical Janus kinase inhibitors (JAKi) have recently been FDA-approved for refractory nonsegmental vitiligo, use of systemic JAKi remains novel. This systematic review summarizes evidence regarding this indication.

Categories

Licence